Document is current
Any future updates will be listed below
-
Authors
Schwartz, Evan A. https://orcid.org/0000-0002-7468-9010
Bravo, Jack P. K. https://orcid.org/0000-0003-0456-0753
Ahsan, Mohd https://orcid.org/0000-0002-0583-4413
Macias, Luis A. https://orcid.org/0000-0003-1949-6029
McCafferty, Caitlyn L. https://orcid.org/0000-0002-0872-4527
Dangerfield, Tyler L. https://orcid.org/0000-0003-1413-2082
Walker, Jada N. https://orcid.org/0000-0001-6233-3124
Brodbelt, Jennifer S. https://orcid.org/0000-0003-3207-0217
Palermo, Giulia https://orcid.org/0000-0003-1404-8737
Fineran, Peter C. https://orcid.org/0000-0002-4639-6704
Fagerlund, Robert D. https://orcid.org/0000-0002-3939-1489
Taylor, David W. https://orcid.org/0000-0002-6198-1194
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R35GM138348)
- License Information
-
More Information
Article History
Received: 21 August 2023
Accepted: 2 April 2024
First Online: 18 April 2024
Competing interests
: The University of Otago and the Board of Regents for the University at Texas have filed a patent application related to this work titled “Type III-D CRISPR-Cas System and Uses Thereof” (PCT/NZ2023/050059, filed 13 June 2023), where R.D.F., P.C.F., E.A.S., J.P.K.B., and D.W.T. are inventors. All other authors declare that they have no competing interests.
